Wilson disease patients sought for survey to shape gene editing research
NCT ID NCT07226622
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study surveys 30 adults with Wilson disease to learn about their daily management, treatment adherence, and interest in gene editing clinical trials. By gathering this information, researchers hope to design better future studies for potential gene therapies targeting specific ATP7B mutations.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help design better future clinical trials for gene editing treatments in Wilson disease.
- What could go wrong
- This is a small, observational prescreening study with only 30 participants, so it won't directly test any treatment or provide health benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a confirmed diagnosis of Wilson Disease, at least 15 of whom have the p.H1069Q allele.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Confirmed Wilson Disease (WD) as determined by the following criteria: 1. An established clinical diagnosis of WD 2. Genetic analysis confirming the presence of biallelic pathogenic variants at ATP7B, at least one of which is EITHER p.H1069Q OR p.R778L OR Participants without a confirmed genetic diagnosis may enroll only with explicit approval from the Medical Monitor Exclusion Criteria: 1. Prior history of gene therapy, liver transplantation, hepatocyte (cellular) transplantation, or active listing for liver transplantation 2. For individuals with known ATP7B genotype: individual does not have at least 1 ATP7B allele with either the p.H1069Q or p.R778L mutation. 3. Significant neurological conditions within the prior 12 months which may impact participant safety or participation in the study, including ability to complete study requirements or procedures as outlined in the clinical study protocol. 4. In patients with psychiatric involvement, current or fluctuant clinical instability with new or changing diagnoses or substantial medication regimen changes in the past 12 months that could limit their participation, in the opinion of the Investigator. 5. History of cirrhotic decompensation within the past year. 6. Any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the participant or would preclude the participant from successful study completion, including participant unable or unwilling to comply with the protocol requirements. 7. Current participation in an investigational study for the treatment of WD. 8. Prior or active malignancy or myeloproliferative disorder (excluding Stage 1 or lower, fully treated/excised malignant and pre-malignant disease of the skin, cervix or colon. Additionally, any other malignant and pre-malignant disease that the Investigator in consultation with the treating oncologist and study Medical Monitor deem has been fully treated/excised for \> 5 years).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Wilson disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
American Research Corporation
San Antonio, Texas, 78215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of California Davis Health
Sacramento, California, 95817, United States
-
University of California Los Angeles Medical Center
Los Angeles, California, 90027, United States
-
University of Michigan Medicine
Ann Arbor, Michigan, 48109, United States
-
Yale New Haven Hospital
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden heart risks in Wilson's disease: a new scan could spot them early
- Can a One-Time gene fix cure wilson disease?
- Can a single infusion rewrite the genetic code behind wilson disease?
- Newborn screening study aims to catch rare diseases at birth
- Building a database to unlock wilson disease mysteries
- New Free-Breathing MRI could make liver scans easier for kids